Literature DB >> 24292009

Early loss of oligodendrocytes in human and experimental neuromyelitis optica lesions.

Claudia Wrzos1, Anne Winkler, Imke Metz, Dieter M Kayser, Dietmar R Thal, Christiane Wegner, Wolfgang Brück, Stefan Nessler, Jeffrey L Bennett, Christine Stadelmann.   

Abstract

Neuromyelitis optica (NMO) is a chronic, mostly relapsing inflammatory demyelinating disease of the CNS characterized by serum anti-aquaporin 4 (AQP4) antibodies in the majority of patients. Anti-AQP4 antibodies derived from NMO patients target and deplete astrocytes in experimental models when co-injected with complement. However, the time course and mechanisms of oligodendrocyte loss and demyelination and the fate of oligodendrocyte precursor cells (OPC) have not been examined in detail. Also, no studies regarding astrocyte repopulation of experimental NMO lesions have been reported. We utilized two rat models using either systemic transfer or focal intracerebral injection of recombinant human anti-AQP4 antibodies to generate NMO-like lesions. Time-course experiments were performed to examine oligodendroglial and astroglial damage and repair. In addition, oligodendrocyte pathology was studied in early human NMO lesions. Apart from early complement-mediated astrocyte destruction, we observed a prominent, very early loss of oligodendrocytes and oligodendrocyte precursor cells (OPCs) as well as a delayed loss of myelin. Astrocyte repopulation of focal NMO lesions was already substantial after 1 week. Olig2-positive OPCs reappeared before NogoA-positive, mature oligodendrocytes. Thus, using two experimental models that closely mimic the human disease, our study demonstrates that oligodendrocyte and OPC loss is an extremely early feature in the formation of human and experimental NMO lesions and leads to subsequent, delayed demyelination, highlighting an important difference in the pathogenesis of MS and NMO.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24292009      PMCID: PMC4229038          DOI: 10.1007/s00401-013-1220-8

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  45 in total

1.  Involvement of antibody-dependent cell-mediated cytotoxicity in inflammatory demyelination in a mouse model of neuromyelitis optica.

Authors:  Julien Ratelade; Nithi Asavapanumas; Alanna M Ritchie; Scott Wemlinger; Jeffrey L Bennett; A S Verkman
Journal:  Acta Neuropathol       Date:  2013-08-31       Impact factor: 17.088

2.  Multicontrast MRI of remyelination in the central nervous system.

Authors:  Doron Merkler; Susann Boretius; Christine Stadelmann; Tristan Ernsting; Thomas Michaelis; Jens Frahm; Wolfgang Brück
Journal:  NMR Biomed       Date:  2005-10       Impact factor: 4.044

3.  Molecular outcomes of neuromyelitis optica (NMO)-IgG binding to aquaporin-4 in astrocytes.

Authors:  Shannon R Hinson; Michael F Romero; Bogdan F Gh Popescu; Claudia F Lucchinetti; James P Fryer; Hartwig Wolburg; Petra Fallier-Becker; Susan Noell; Vanda A Lennon
Journal:  Proc Natl Acad Sci U S A       Date:  2011-11-29       Impact factor: 11.205

4.  Freeze-fracture and immunogold analysis of aquaporin-4 (AQP4) square arrays, with models of AQP4 lattice assembly.

Authors:  J E Rash; K G V Davidson; T Yasumura; C S Furman
Journal:  Neuroscience       Date:  2004       Impact factor: 3.590

5.  Neuromyelitis optica IgG and natural killer cells produce NMO lesions in mice without myelin loss.

Authors:  Julien Ratelade; Hua Zhang; Samira Saadoun; Jeffrey L Bennett; Marios C Papadopoulos; A S Verkman
Journal:  Acta Neuropathol       Date:  2012-04-22       Impact factor: 17.088

6.  Devic's neuromyelitis optica: a clinicopathological study of 8 patients.

Authors:  R N Mandler; L E Davis; D R Jeffery; M Kornfeld
Journal:  Ann Neurol       Date:  1993-08       Impact factor: 10.422

7.  Eosinophil pathogenicity mechanisms and therapeutics in neuromyelitis optica.

Authors:  Hua Zhang; A S Verkman
Journal:  J Clin Invest       Date:  2013-04-08       Impact factor: 14.808

8.  Neuromyelitis optica: Passive transfer to rats by human immunoglobulin.

Authors:  Makoto Kinoshita; Yuji Nakatsuji; Takashi Kimura; Masayuki Moriya; Kazushiro Takata; Tatsusada Okuno; Atsushi Kumanogoh; Koji Kajiyama; Hiroo Yoshikawa; Saburo Sakoda
Journal:  Biochem Biophys Res Commun       Date:  2009-06-21       Impact factor: 3.575

9.  Pathogenic T cell responses against aquaporin 4.

Authors:  Maria Pohl; Marie-Therese Fischer; Simone Mader; Kathrin Schanda; Maja Kitic; Rakhi Sharma; Isabella Wimmer; Tatsuro Misu; Kazuo Fujihara; Markus Reindl; Hans Lassmann; Monika Bradl
Journal:  Acta Neuropathol       Date:  2011-04-06       Impact factor: 17.088

10.  IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel.

Authors:  Vanda A Lennon; Thomas J Kryzer; Sean J Pittock; A S Verkman; Shannon R Hinson
Journal:  J Exp Med       Date:  2005-08-08       Impact factor: 14.307

View more
  26 in total

1.  Noninvasive, Targeted Creation of Neuromyelitis Optica Pathology in AQP4-IgG Seropositive Rats by Pulsed Focused Ultrasound.

Authors:  Xiaoming Yao; Matthew S Adams; Peter D Jones; Chris J Diederich; Alan S Verkman
Journal:  J Neuropathol Exp Neurol       Date:  2019-01-01       Impact factor: 3.685

Review 2.  Treatment of neuromyelitis optica: state-of-the-art and emerging therapies.

Authors:  Marios C Papadopoulos; Jeffrey L Bennett; Alan S Verkman
Journal:  Nat Rev Neurol       Date:  2014-08-12       Impact factor: 42.937

3.  Blood-brain barrier resealing in neuromyelitis optica occurs independently of astrocyte regeneration.

Authors:  Anne Winkler; Claudia Wrzos; Michael Haberl; Marie-Theres Weil; Ming Gao; Wiebke Möbius; Francesca Odoardi; Dietmar R Thal; Mayland Chang; Ghislain Opdenakker; Jeffrey L Bennett; Stefan Nessler; Christine Stadelmann
Journal:  J Clin Invest       Date:  2021-03-01       Impact factor: 14.808

Review 4.  Heterogeneity in oligodendroglia: Is it relevant to mouse models and human disease?

Authors:  Isis M Ornelas; Lauren E McLane; Aminat Saliu; Angelina V Evangelou; Luipa Khandker; Teresa L Wood
Journal:  J Neurosci Res       Date:  2016-08-25       Impact factor: 4.164

5.  The intrinsic pathogenic role of autoantibodies to aquaporin 4 mediating spinal cord disease in a rat passive-transfer model.

Authors:  Christian Geis; Christian Ritter; Christoph Ruschil; Andreas Weishaupt; Benedikt Grünewald; Guido Stoll; Trygve Holmoy; Tatsuro Misu; Kazuo Fujihara; Bernhard Hemmer; Christine Stadelmann; Jeffrey L Bennett; Claudia Sommer; Klaus V Toyka
Journal:  Exp Neurol       Date:  2014-12-24       Impact factor: 5.330

Review 6.  Neuromyelitis Optica: Deciphering a Complex Immune-Mediated Astrocytopathy.

Authors:  Jeffrey L Bennett; Gregory P Owens
Journal:  J Neuroophthalmol       Date:  2017-09       Impact factor: 3.042

7.  P2R Inhibitors Prevent Antibody-Mediated Complement Activation in an Animal Model of Neuromyelitis Optica : P2R Inhibitors Prevent Autoantibody Injury.

Authors:  Sudhakar Reddy Kalluri; Rajneesh Srivastava; Selin Kenet; Goutam K Tanti; Klaus Dornmair; Jeffrey L Bennett; Thomas Misgeld; Bernhard Hemmer; Matthias T Wyss; Marina Herwerth
Journal:  Neurotherapeutics       Date:  2022-07-12       Impact factor: 6.088

8.  Bystander mechanism for complement-initiated early oligodendrocyte injury in neuromyelitis optica.

Authors:  Lukmanee Tradtrantip; Xiaoming Yao; Tao Su; Alex J Smith; Alan S Verkman
Journal:  Acta Neuropathol       Date:  2017-05-31       Impact factor: 17.088

Review 9.  The treatment of neuromyelitis optica.

Authors:  Markus C Kowarik; John Soltys; Jeffrey L Bennett
Journal:  J Neuroophthalmol       Date:  2014-03       Impact factor: 3.042

10.  Sera from Patients with NMOSD Reduce the Differentiation Capacity of Precursor Cells in the Central Nervous System.

Authors:  Ulises Gómez-Pinedo; Yolanda García-Ávila; Lucía Gallego-Villarejo; Jordi A Matías-Guiu; María Soledad Benito-Martín; Noelia Esteban-García; Inmaculada Sanclemente-Alamán; Vanesa Pytel; Lidia Moreno-Jiménez; Francisco Sancho-Bielsa; Lucía Vidorreta-Ballesteros; Paloma Montero-Escribano; Jorge Matías-Guiu
Journal:  Int J Mol Sci       Date:  2021-05-14       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.